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and assessing their quality
In the recent JAMIA article ‘Measuring
value for money: a scoping review on eco-
nomic evaluation of health information
systems (HIS),’ Bassi and Lau1 identiﬁed
42 studies conducted from different per-
spectives within public, private and mixed
healthcare systems and assessed 33 of
them as good quality. The importance of
establishing value for money of large HIS
investments is indisputable. Numerous
assessments of economic aspects of differ-
ent HIS implementations have been con-
ducted; however, there is a paucity of
reviews classifying and summarizing their
results. Bassi and Lau’s review makes a
useful contribution by introducing a new
methodological framework, which classi-
ﬁes HIS studies with an ‘economic com-
ponent’ and assesses their quality. In our
view, the framework has some limitations
that may confuse readers and result in
misguided conclusions. Here we brieﬂy
discuss these limitations and we hope this
will stimulate further discussion.
One of the central challenges is that
many HIS studies, including those identi-
ﬁed by Bassi and Lau, contain some infor-
mation on beneﬁts and/or costs, but such
studies were often not designed to
conduct an economic evaluation or assess
economic efﬁciency as deﬁned by the eco-
nomics discipline. The stated objectives
and the correspondent methods (eg,
econometric modelling) may be sufﬁcient
to quantify ‘cost savings’ associated with
investing in HIS, but cannot show that the
investment is economically efﬁcient (ie,
provides better value than the alternative
use of resources). Readers may incorrectly
interpret results of such studies as evi-
dence of economic efﬁciency. It would be
helpful to establish what is required to
demonstrate ‘value for money’ of HIS,
and how to differentiate between studies
that set out, and achieve, this objective
from those studies that serve other, also
useful, purposes. For example, in an
earlier systematic review Shekelle and col-
leagues2 identiﬁed 256 studies on costs
and beneﬁts of health information tech-
nology and used a multidimensional clas-
siﬁcation which, among other criteria,
included study objectives and analytic
techniques employed by the reviewed
studies—namely, ‘predictive analysis’,
‘hypothesis-testing’, and ‘meta-analysis’.
In the absence of a conventional frame-
work for categorizing HIS economic
studies and assessing their quality, Bassi
and Lau used the health economics frame-
work of Drummond and colleagues3 and
supplemented it with the usual criteria for
assessing academic papers. Drummond
and colleagues developed their framework
over many years by numerous discussions,
consultations, and meetings with academic
experts, clinicians, and editors of leading
medical journals.4 This widely accepted
and extensively used framework includes
a classiﬁcation of health economic evalu-
ation studies and a checklist for assessing
their quality.
The classiﬁcation is based on mutually
exclusive categories and distinguishes full
economic evaluations (cost-effectiveness
analysis (CEA), cost-utility (CUA), and cost-
beneﬁt (CBA) analyses) from partial
economic evaluations (eg, cost analyses or
cost-outcome descriptions). Full economic
evaluation is a comparative analysis of alter-
native options/programmes that involves
identiﬁcation, measurement, and valuation
of both costs and outcomes, and establishes
the difference in costs in relation to differ-
ence in outcomes in an incremental
fashion. Results of economic analyses are
expressed as an incremental cost-effective-
ness ratio, net monetary beneﬁt, or net
health beneﬁt.3 Conducted from a societal
perspective (ie, including all costs and con-
sequences, regardless of who bears them),
health economic evaluations are consistent
with the economic theory of maximizing
social welfare, because by allocating limited
resources to interventions with the lowest
cost per unit of health gain, decision-
makers can increase the total health and
well-being of the society.
Drummond’s economic evaluation
study checklist includes quality assessment
criteria (eg, whether the costs and out-
comes for each alternative option were
well deﬁned, whether the perspective of
the analysis was stated, whether discount-
ing of costs and outcomes for a speciﬁed
time frame was conducted). Bassi and Lau
selected ﬁve of these criteria (perspective
of the analysis, a speciﬁed time frame,
presence of an alternative option for com-
parison, assessment of costs and outcomes)
to identify some of the reviewed studies as
‘economic analyses’. Their sixth criterion
stated that costs and outcomes should be
compared for each option. Thus this sixth
criterion called for an average cost-
effectiveness ratio rather than an incre-
mental cost-effectiveness ratio. However,
an average cost-effectiveness ratio is likely
to underestimate the cost for each add-
itional unit of outcome compared with an
incremental cost-effectiveness ratio.3
Using their deﬁnition of economic ana-
lysis, the authors identiﬁed only one CUA,
two CEAs and six CBAs, while most
studies (21 studies) were classiﬁed as
either ‘input cost analysis’ or ‘cost-related
outcome analysis’. Although the latter
term resembles Drummond’s ‘cost-
outcome description’, it is rather ambigu-
ous as some papers could be classiﬁed as
both an ‘input cost analysis’ and ‘cost-
related outcome analysis’. Some of the
high-quality ‘hypothesis-testing’ papers
that investigated associations between
adoption of HIS and potential cost
savings fell into this category. However, as
argued above, no amount of cost savings
provides evidence of economic efﬁciency
unless the alternative use of resources and
associated outcomes is considered.
The difﬁculties experienced by Bassi
and Lau in adequately identifying and
classifying HIS studies with an economic
component, suggest that Drummond’s
framework may apply only to studies that
were conducted to demonstrate economic
efﬁciency by explicitly comparing two
options in an incremental fashion. This is
not to say that other HIS economic
studies are unimportant. Full economic
evaluation is not the only method of esti-
mating costs and beneﬁts. Society may be
concerned with improving technical and
productive efﬁciency from the resources
that have already been allocated; however,
to avoid confusion such studies should be
differentiated accordingly.
This letter is written with the intention of
stimulating further discussion about frame-
works for categorizing HIS economic
studies and assessing their quality. The
framework needs to be sensitive to the
stated objectives of HIS economic papers
and speciﬁc enough to minimize ambiguity
in allocating studies into categories.
Reaching greater agreement about a frame-
work is important for both assessing current
evidence and guiding future research.
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